arrow
B

Benedetta Pellegrino

University of Molise
H指数:18
被引数:1,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026-01-010
PRE
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy

SARS-CoV-2感染风险及COVID-19患病率与死亡率:意大利北部疫情中心第一波COVID-19大流行期间癌症患者研究

CANCERS
IF4.4
2025-05-010
OA
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
2025-01-011
OAAI
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
2024-05-141
PRE
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

激素受体阳性/HER2-Positive乳腺癌: 激素治疗和Anti-HER2治疗: 治疗策略的更新

2024-03-245
OAAI
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients

乳腺癌患者曲妥珠单抗deruxtecan (t-dxd) 诱导的间质性肺疾病 (ILD) 的主动监测,早期诊断和有效管理的多学科临床指南

2023-12-0115
OAAI
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

BRCA2种系突变鉴定对PARP抑制剂有反应的胃癌

2023-05-026
OAAI
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
2022-10-0121
OAAI
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

用于鉴定同源重组缺陷肿瘤和患者分层的RAD51测试的临床前体内验证

2022-02-1645
OA